NUWE

+ Watchlist + Portfolio

Nuwellis, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.75
52-Week Range: $0.69 – $172.90
Market Cap: $2.53M
P/E (TTM): 0.00
EPS (TTM): 435.92
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -87.83%
Gross Margin: 69.69%
Operating Margin: -160.95%
Profit Margin: -125.63%
Current Ratio: 1.97
Debt/Equity: —
Total Debt: $200.00K
Free Cash Flow: $-11.44M
Revenue Growth: 14.10%
Earnings Growth: —
Enterprise Value: $-1.18M

NUWE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.54M	$8.86M	$8.74M	$8.27M
Cost of Revenue	$3.79M	$3.88M	$3.06M	$3.15M
Gross Profit	$4.75M	$4.98M	$5.68M	$5.12M
Research & Development	$4.34M	$5.42M	$3.21M	$2.71M
Selling, General & Admin	$17.58M	$17.19M	$13.46M	$13.52M
Operating Expenses	$21.93M	$22.61M	$16.66M	$16.23M
Operating Income	-$17.17M	-$17.63M	-$10.99M	-$11.11M
EBITDA	-$4.90M	-$16.36M	-$5.24M	-$6.55M
Pretax Income	-$14.52M	-$20.20M	-$11.16M	-$17.52M
Income Tax	$9.00K	$8.00K	$5.00K	$5.00K
Net Income	-$14.53M	-$20.21M	-$11.16M	-$17.52M
Diluted EPS	-947.80	-16934.40	-3571.09	-888.65
Diluted Shares	10	110	2975	19718

NUWE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.74M	$3.80M	$5.09M	$1.08M
Receivables	$1.41M	$1.95M	$1.73M	$1.49M
Inventory	$2.66M	$2.00M	$1.72M	$1.91M
Current Assets	$22.77M	$8.21M	$8.86M	$5.19M
Total Assets	$24.67M	$9.77M	$9.86M	$6.12M
Current Liabilities	$4.69M	$3.17M	$2.56M	$3.03M
Total Debt	$984.00K	$760.00K	$545.00K	$328.00K
Total Liabilities	$12.32M	$6.56M	$3.33M	$3.49M
Retained Earnings	-$267.42M	-$287.63M	-$298.79M	-$316.31M
Shareholders' Equity	$12.36M	$3.21M	$6.53M	$2.63M
Working Capital	$18.08M	$5.04M	$6.30M	$2.15M

NUWE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.15M	-$17.94M	-$9.59M	-$10.81M
Capital Expenditure	-$122.00K	-$248.00K	-$60.00K	-$90.00K
Free Cash Flow	-$15.27M	-$18.18M	-$9.65M	-$10.90M
Depreciation & Amortisation	$372.00K	$362.00K	$310.00K	$417.00K
Stock-Based Compensation	$862.00K	$670.00K	$478.00K	$127.00K
Investing Cash Flow	$14.73M	$330.00K	-$60.00K	-$90.00K
Financing Cash Flow	$9.42M	$3.68M	$10.96M	$6.94M
Net Change in Cash	$9.00M	-$13.92M	$1.31M	-$3.96M

NUWE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.90M	$1.73M	$2.22M	$2.42M	$2.40M	$1.97M
Cost of Revenue	$837.00K	$767.00K	$772.00K	$770.00K	$719.00K	$471.00K
Gross Profit	$1.07M	$958.00K	$1.45M	$1.65M	$1.68M	$1.50M
Research & Development	$550.00K	$675.00K	$603.00K	$884.00K	$1.73M	$942.00K
Selling, General & Admin	$3.58M	$3.19M	$3.54M	$3.21M	$4.52M	$3.73M
Operating Expenses	$4.13M	$3.86M	$4.14M	$4.10M	$6.25M	$4.67M
Operating Income	-$3.06M	-$2.91M	-$2.70M	-$2.44M	-$4.57M	-$3.17M
EBITDA	-$2.99M	-$1.95M	$672.00K	-$2.33M	-$4.53M	$1.29M
Pretax Income	-$3.01M	-$12.55M	$468.00K	-$2.42M	-$4.54M	-$4.83M
Income Tax	$1.00K	$4.00K	$0.00	$0.00	$0.00	$0.00
Net Income	-$3.01M	-$12.55M	$468.00K	-$2.42M	-$4.54M	-$4.83M
Diluted EPS	-1014.30	-2134.19	19.60	-52.50	-73.15	-26.64
Diluted Shares	2975	5881	23896	46120	59284	181243

NUWE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.56M	$4.45M	$3.09M	$1.08M	$2.08M	$3.92M
Receivables	$1.54M	$1.19M	$1.14M	$1.49M	$1.56M	$1.54M
Inventory	$1.75M	$2.03M	$2.19M	$1.91M	$1.78M	$1.74M
Current Assets	$6.12M	$8.42M	$7.20M	$5.19M	$5.83M	$7.90M
Total Assets	$7.01M	$9.20M	$7.98M	$6.12M	$6.96M	$9.13M
Current Liabilities	$2.75M	$3.89M	$3.52M	$3.03M	$3.73M	$4.01M
Total Debt	$492.00K	$438.00K	$383.00K	$328.00K	$265.00K	$200.00K
Total Liabilities	$3.42M	$18.16M	$4.07M	$3.49M	$4.29M	$11.17M
Retained Earnings	-$301.81M	-$314.36M	-$313.89M	-$316.31M	-$320.85M	-$325.68M
Shareholders' Equity	$3.58M	-$8.96M	$3.91M	$2.63M	$2.67M	-$2.04M
Working Capital	$3.37M	$4.52M	$3.68M	$2.15M	$2.10M	$3.89M

NUWE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.54M	-$2.10M	-$3.15M	-$3.03M	-$3.11M	-$3.17M
Capital Expenditure	—	—	-$98.00K	—	-$120.00K	-$9.00K
Free Cash Flow	-$2.54M	-$2.10M	-$3.25M	-$3.02M	-$3.23M	-$3.18M
Depreciation & Amortisation	$73.00K	$50.00K	$204.00K	$90.00K	$38.00K	$37.00K
Stock-Based Compensation	$67.00K	$17.00K	$19.00K	$24.00K	$25.00K	$22.00K
Investing Cash Flow	$0.00	-$4.00K	-$98.00K	$12.00K	-$284.00K	-$9.00K
Financing Cash Flow	$0.00	$4.00M	$1.89M	$1.05M	$4.39M	$5.02M
Net Change in Cash	-$2.54M	$1.90M	-$1.36M	-$1.97M	$999.00K	$1.84M

Market Snapshot

About

Nuwellis, Inc. is a medical device company focused on ultrafiltration therapy for fluid overload management. The company develops and markets the Aquadex FlexFlow system for treating hypervolemia in heart failure and other conditions.